Turn off the IDO: Will clinical trials be successful?

Cancer Discovery

Volumn 2, Issue 8, 2012, Pages 673-675

  Novitskiy, Sergey V ^a   Moses, Harold L ^a  

^a VANDERBILT UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CHEMOKINE RECEPTOR CCR2; CYCLOOXYGENASE 2; DENDRITIC CELL VACCINE; DOCETAXEL; GELATINASE B; INDOLEAMINE 2, 3 DIOXYGENASE; INDOLEAMINE 2, 3 DIOXYGENASE 1; INDOLEAMINE 2, 3 DIOXYGENASE INHIBITOR; INTERLEUKIN 6; KYNURENINE; MONOCYTE CHEMOTACTIC PROTEIN 1; N METHYLTRYPTOPHAN; UNCLASSIFIED DRUG;

ANGIOGENESIS; ARTICLE; CANCER PROGNOSIS; CARCINOGENESIS; CELL PROLIFERATION; CLINICAL RESEARCH; DENDRITIC CELL; DOWN REGULATION; GENE OVEREXPRESSION; HUMAN; LUNG CANCER; MACROPHAGE; METASTASIS; NONHUMAN; SKIN CANCER; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR GROWTH;

ANIMALS; HUMANS; INDOLEAMINE-PYRROLE 2,3,-DIOXYGENASE; LUNG NEOPLASMS;

EID: 84866236943     PISSN: 21598274     EISSN: 21598290     Source Type: Journal    
DOI: 10.1158/2159-8290.CD-12-0311     Document Type: Article

References (12)

1. Fallarino F, Grohmann U, You S, McGrath BC, Cavener DR, Vacca C, et al. The combined effects of tryptophan starvation and tryptophan catabolites down-regulate T cell receptor zeta-chain and induce a regulatory phenotype in naive T cells. J Immunol 2006;176:6752-61.
2. de Jong RA, Kema IP, Boerma A, Boezen HM, der Want JJ, Gooden MJ, et al. Prognostic role of indoleamine 2,3-dioxygenase in endometrial carcinoma. Gynecol Oncol. 2012 Jun 2. [Epub ahead of print].
3. Muller AJ, DuHadaway JB, Donover PS, Sutanto-Ward E, Prendergast GC. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat Med 2005;11:312-9.
4. Shirey KA, Jung JY, Maeder GS, Carlin JM. Upregulation of IFNgamma receptor expression by proinflammatory cytokines influences IDO activation in epithelial cells. J Interferon Cytokine Res 2006;26:53-62.
5. Munn DH. Indoleamine 2,3-dioxygenase, tumor-induced tolerance and counter-regulation. Curr Opin Immunol 2006;18:220-5.
6. Hou DY, Muller AJ, Sharma MD, DuHadaway J, Banerjee T, Johnson M, et al. Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses. Cancer Res 2007;67:792-801.
7. Smith C, Chang MY, Parker KH, Beury DW, DuHadaway JB, Flick HE, et al. IDO is a nodal pathogenic driver of lung cancer and metastasis development. Cancer Discov 2012;2:722-35.
8. Muller AJ, Sharma MD, Chandler PR, Duhadaway JB, Everhart ME, Johnson BA III, et al. Chronic inflammation that facilitates tumor progression creates local immune suppression by inducing indoleamine 2,3 dioxygenase. Proc Natl Acad Sci U S A 2008;105:17073-8.
9. Mei J, Jin LP, Ding D, Li MQ, Li DJ, Zhu XY. Inhibition of IDO1 suppresses cyclooxygenase-2 and matrix metalloproteinase-9 expression and decreases proliferation, adhesion and invasion of endometrial stromal cells. Mol Hum Reprod 2012.
10. Lu X, Kang Y. Chemokine (C-C motif) ligand 2 engages CCR2+ stromal cells of monocytic origin to promote breast cancer metastasis to lung and bone. J Biol Chem 2009;284:29087-96.
11. Qian BZ, Li J, Zhang H, Kitamura T, Zhang J, Campion LR, et al. CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis. Nature 2011;475:222-5.
12. Levina V, Su Y, Gorelik E. Immunological and nonimmunological effects of indoleamine 2,3-dioxygenase on breast tumor growth and spontaneous metastasis formation. Clin Dev Immunol 2012;2012:173029.